OPKO Health, Inc. Restricted Cash and Cash Equivalents, Noncurrent
OPKO Health, Inc. (OPK) had Restricted Cash and Cash Equivalents, Noncurrent of $13.67 million as of 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2026-08-28
- 2026-06-30: Restricted Cash and Cash Equivalents, Noncurrent $13.67M.
- 2026-03-31: Restricted Cash and Cash Equivalents, Noncurrent $13.69M.
- 2025-12-31: Restricted Cash and Cash Equivalents, Noncurrent $13.67M.
- 2025-09-30: Restricted Cash and Cash Equivalents, Noncurrent $13.68M.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2026-06-30 | $13.67M 10-Q/A · filed 2026-08-28 |
| 2026-03-31 | $13.69M 10-Q/A · filed 2026-08-28 |
| 2025-12-31 | $13.67M 10-Q/A · filed 2026-08-28 |
| 2025-09-30 | $13.68M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $13.68M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $13.68M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $13.68M 10-K · filed 2026-02-26 |
| 2024-09-30 | $13.66M 10-Q · filed 2024-11-07 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |